Methionine synthase supports tumor tetrahydrofolate pools

Joshua Z. Wang^{1,2,#}, Jonathan M. Ghergurovich^{1,3,#}, Lifeng Yang^{1,2}, and Joshua D. Rabinowitz^{1,2,}*

¹ Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey, USA

² Department of Chemistry, Princeton University, Princeton, New Jersey, USA

³ Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA

These authors contributed equally to this work.

*Corresponding author:

Joshua Rabinowitz

Department of Chemistry and the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Washington Rd, Princeton, NJ 08544, USA

Phone: (609) 258-8985; e-mail: joshr@princeton.edu

Conflict of Interest Disclosure: J.D.R. is a paid advisor and stockholder in Kadmon Pharmaceuticals, L.E.A.F. Pharmaceuticals, and Rafael Pharmaceuticals; a paid consultant of Pfizer; a founder, director, and stockholder of Farber Partners and Serien Therapeutics. JDR and JMG are inventors of patents in the area of folate metabolism held by Princeton University.

Abstract

Mammalian cells require activated folates to generate nucleotides for growth and division. The most abundant circulating folate species is 5-methyl tetrahydrofolate (5-methyl-THF), which is used to synthesize methionine from homocysteine via the cobalamin-dependent enzyme methionine synthase (MTR). Cobalamin deficiency traps folates as 5-methyl-THF. Here, we show using isotope tracing that methionine synthase is only a minor source of methionine in cell culture, tissues, or xenografted tumors. Instead, methionine synthase is required for cells to avoid folate trapping and assimilate 5-methyl-THF into other folate species. Under conditions of physiological extracellular folates, genetic MTR knockout in tumor cells leads to folate trapping, purine synthesis stalling, nucleotide depletion, and impaired growth in cell culture and as xenografts. These defects are rescued by free folate but not one-carbon unit supplementation. Thus, MTR plays a crucial role in liberating tetrahydrofolate for use in one-carbon metabolism.

Introduction

Dividing cells require activated one-carbon (1C) units to synthesize and package nucleic acids [1]. In mammals, tetrahydrofolate (THF) species carry the formyl- and methylene- 1C groups necessary for purine and thymidylate biosynthesis [2-4]. This essentiality is reflected in the efficacy of antifolate chemotherapeutic agents for treating malignancy, their associated toxicities in proliferating normal tissues, and alleviation of these effects by folate rescue agents (i.e. 5-formyl-THF, a.k.a. leucovorin) [5]. The 1C units of activated folates are locally sourced from serine, glycine, and other amino acids [6, 7], with the major 1C donor typically serine via the enzyme serine hydroxymethyltransferase (SHMT).

In contrast to the capacity to manipulate 1C units using THF, mammals lack the necessary machinery for *de novo* folate synthesis. Folate species are instead absorbed from food and converted in the gut and liver to 5-methyl tetrahydrofolate (5-methyl-THF), the dominant circulating folate species, before distributing to tissue folate pools [8, 9]. Deficiency in dietary folate causes neural tube defects during pregnancy [10].

Mammals also lack the ability to assimilate inorganic sulfur, and thus have a daily requirement for sulfur containing amino acids like methionine [11-13]. In addition to its role in protein synthesis, methionine serves as the primary methyl source for DNA, protein, and lipid methylation via S-adenosyl-methionine (SAM) [14]. Methyl donation by SAM ultimately yields the free thiol species homocysteine, which undergoes either degradation via the transsulfuration pathway to yield cysteine or remethylation to methionine [11]. SAM also acts as an allosteric regulator, inhibiting methylenetetrahydrofolate reductase (MTHFR), the enzyme producing 5-methyl-THF, and activating cystathionine β -synthase (CBS), the first enzyme of transsulfuration [15, 16]. Low SAM accordingly tends to preserve homocysteine and promote its conversion to methionine, allowing homocysteine to substitute for dietary methionine [17-19].

Methionine synthase (MTR) catalyzes the methyl transfer from 5-methyl-THF to homocysteine, yielding methionine and tetrahydrofolate (THF), linking folate and methionine cycling [11, 20] (Figure 1A). MTR is one of two enzymes in humans known to utilize the cofactor vitamin B₁₂ (cobalamin) [21]. Mutations in *MTR* leading to diminished enzyme activity result in methylcobalamin deficiency G (cblG) disorder, a condition characterized by hyperhomocysteinemia, hypomethioninemia and homocystinuria [22]. In development, *Mtr* is

essential, leading to embryonic death in mice [23]. MTR is universally expressed in tissues, while expression of betaine-homocysteine S-methyltransferase (BHMT), the other enzyme known to produce methionine via methyl transfer from betaine to homocysteine, is primarily expressed in the liver and, to a lesser degree, in the kidney ([15, 24-26]; Figure 1B). Similarly, MTR is broadly expressed in human cancer cell lines [27] and tumors [28].

The physiological role of MTR is evident from vitamin B₁₂ deficiency. Classically, B₁₂-deficient patients present with neurological and hematological manifestations, most notably a macrocytic, megaloblastic anemia, an indicator of impaired nucleotide synthesis. This phenotype similarly occurs in folate deficiency [29, 30]. Vitamin B₁₂ restriction or chemical inactivation of vitamin B₁₂ (and thus MTR) by nitrous oxide impairs MTR activity *in vitro* and *in vivo* [30-32]. Moreover, because methylene-THF reduction to 5-methyl-THF is nearly irreversible in cells (due to high cytosolic NADPH/NADP⁺) [33], MTR dysfunction leads to folate trapping as 5-methyl-THF [20, 30, 34-36].

Despite numerous studies over the last 70 years into folate and methionine metabolism, it is unclear how much methionine arises locally from remethylation in a given tissue. Similarly, the role of MTR in supporting cancer growth has not yet been robustly examined. Here, we combine modern genetic tools with isotope tracer studies to dissect the role of MTR in normal tissue and tumor biology. We show that tissue and tumor methionine is overwhelmingly acquired from the systemic circulation, with MTR contributing only a minor fraction to local methionine pools. Conversely, MTR plays a major role in maintaining folate pools, with cells and xenografted tumors lacking MTR unable to grow when subjected to physiological folate conditions. Mechanistically, we show that MTR loss leads to folate trapping, purine synthesis stalling and nucleotide depletion, which can be mitigated with folate rescue agents.

Results

Methionine comes mainly from uptake rather than homocysteine remethylation

Methionine cycling involves reduction of 5,10-methylene-THF to 5-methyl-THF mediated by MTHFR, followed by conversion of homocysteine to methionine by MTR. Alternatively, homocysteine can be converted to methionine by betaine hydroxymethyltransferase (BHMT) (Figure 1A). MTR is expressed throughout the body, while BHMT is preferentially expressed in liver (Figure 1B).

To probe methionine cycling, we began with cell culture experiments where the media methionine component was substituted for [U-¹³C]methionine at the same concentration. We reasoned that untransformed methionine would retain all five labeled carbons (M+5). In contrast, methionine that had been recycled via homocysteine remethylation would lose one ¹³C carbon, retaining four labeled carbons (M+4; Figure 1A, Supplementary figure S1A). The fraction of M+4 to M+5 methionine approximates the relative amount of cellular methionine arising via remethylation as opposed to uptake. All cell lines examined displayed a high fraction of M+5 and low fraction of M+4 methionine (<3%), consistent with intracellular methionine mainly arising from uptake (Figure 1C). Similar experiments with either [U-¹³C]- or [3-¹³C]serine tracing, looking for M+1 methionine coming from homocysteine remethylation via the SHMT-MTHFR-MTR pathway (Supplementary figure S1B) showed very low levels of enrichment (<1% enrichment) (Supplementary figure S1C). Thus, consistent with prior literature, methionine cycling is minimal in cell culture[3, 37].

To examine whether these observations hold *in vivo*, we infused [U-¹³C]methionine via jugular venous catheter into C57BL/6J mice bearing subcutaneous pancreatic ductal adenocarcinoma (PDAC) allograft tumors [38], achieving an enrichment of 30-60% in serum, tumors and most tissues (Figure 1D). This extent of labeling is adequate for robust label detection while avoiding severe metabolic perturbation by the labeled methionine infusion. In all tissues except liver, M+5 labeling was dominant, with M+4/M+5 ratio about 0.1, suggesting that approximately 10% of methionine arose from homocysteine remethylation (Figure 1D). The fraction of M+4 was similar between serum and these tissues, and thus does not necessarily reflect tumor-intrinsic methionine cycling. In contrast, liver M+5 labeling was markedly lower

and M+4 higher, resulting in a M+4/M+5 ratio of ~0.6 and consistent with substantial methionine arising via homocysteine remethylation. However, infusion of labeled serine demonstrated limited folate-mediated methionine synthesis throughout the body, including the liver (Supplementary figure S1E). Thus, homocysteine remethylation in the liver must utilize a different methyl donor.

We next sought to assess the contribution of remethylated methionine from betaine, the alternative source of methionine in mammals. The BHMT reaction transfers a methyl group from the quaternary amine of betaine to homocysteine via a cobalamin-independent reaction mechanism [39]. Mice were infused with the [U-²H]betaine tracer, which contains three deuterium (²H) on each methyl group and thus will give rise to M+3 labeled methionine (Supplementary figure 1F). This infusion revealed preferential methionine synthesis from betaine in liver (Figure 1E, Supplementary figure 1G). Collectively, these studies support BHMT being a source of liver methionine while the MTHFR-MTR pathway operates more broadly throughout the body but, at least acutely, makes only a small contribution to methionine overall.

MTR is required for cell growth using physiological folates

The above studies raised questions about the physiological role of the MTHFR-MTR pathway, since it was not a dominant methionine producer anywhere in the body. As an alternative strategy to examine the role of MTR, we generated clonal MTR knockout cell lines (Δ MTR) using CRISPR-Cas9 gene editing in three cancer cell backgrounds: HCT-116 (colorectal carcinoma), 8988T (pancreatic ductal carcinoma), and HepG2 (hepatocellular carcinoma) (Figure 2A). Each of these parental cell lines possesses reasonable expression of MTR (Supplementary figure S2A). In standard tissue culture media formulations containing folic acid, each of these MTR knockout lines grew reasonably well, albeit at slower rates than control cells in the 8988T and HepG2 backgrounds (Figure 2B). Expectedly, neither MTR knockout or control lines grew in the complete absence of folates (Supplementary figure S2B). Control cells were, however, able to grow rapidly in media where folic acid was replaced with 5-methyl-THF, the most abundant circulating folate species. In contrast, MTR knockout cells did not grow at all (Figure 2B). The defective growth of the MTR knockout cells was fully rescued through supplementation with 5-formyl-THF (leucovorin) (Figure 2B), a folate species that enters folate

metabolism independently of MTR. Thus, MTR is required for cancer cell growth using 5-methyl-THF, the main circulating folate species, presumably because MTR is required to liberate THF from 5-methyl-THF.

In addition to 5-methyl-THF, other species such as folic acid and 5-formyl-THF are present in serum at lower concentrations [40]. To investigate whether MTR is required for tumor growth *in vivo*, we implanted HCT116 Δ MTR cells subcutaneously into the lateral flanks of nude mice and monitored their growth. Tumors derived from MTR knockout cells demonstrated a growth deficiency (Figure 2C, Supplementary figure S2C-D), implicating MTR as being important for folate access in the presence of the physiological mixture of circulating folates.

Loss of MTR depletes cells and tumors of reduced folate species

These above findings support the hypothesis that MTR is required to supply cancer cells with free THF when fed 5-methyl-THF, the most abundant physiologically relevant folate species. To evaluate this further, we measured cellular folate species in HCT116 cells cultured with either folic acid or 5-methyl-THF as the sole media folate source. Expectedly, MTR loss led to a significant buildup of 5-methyl-THF in both media conditions (Figure 3A), in line with the concept of “methyl trapping.” Concurrently, most downstream folate species were substantially decreased. The most depleted species was 5,10-methylene-THF, which is required for thymidine biosynthesis. In contrast, 10-formyl-THF, which is used for purine synthesis, was not strongly depleted. This likely reflects inhibition of 10-formyl-THF consumption by purine pathway disruption due to overall folate species dysregulation. Interestingly, buildup of 5-methyl-THF and depletion of other folate species was triggered by MTR loss in cells growing in media containing folic acid, indicating the importance of MTR for folate pool homeostasis even when adequate free folate is available.

In vivo, 5-methyl-THF was elevated ~12-fold in HCT116 Δ MTR-1 tumors when compared to control-1 tumors, while all other folate species were depleted by about 50-80% (Figure 3B). Thus, MTR is required to maintain folate pools under physiological folate conditions.

MTR activity prevents stalling of purine and pyrimidine biosynthesis

We next sought to investigate the downstream effects of MTR loss and associated changes in folate species concentrations on other aspects of cellular metabolism. To this end, HCT116

Δ MTR cells and controls were cultured in media containing either folic acid or 5-methyl-THF as the sole media folate. Metabolomics demonstrated global changes in metabolism due to MTR loss (Supplementary figure S3A). Most notably, we observed dramatic increases in several purine biosynthetic intermediate pools, including GAR, SAICAR and AICAR (Figure 4A), and corresponding decreases in nucleotide species (Figure 4B, Supplementary figure S3B). Nucleotide depletion was most substantial in media containing 5-methyl-THF as the sole folate source. Similarly, MTR loss in folic acid media led to a buildup of dUMP, consistent with impaired thymidine biosynthesis secondary to diminished 5,10-methylene-THF, though the thymidylate species dTMP and dTTP were unperturbed (Supplementary figure S3C). Interestingly, both dUMP and dTMP/dTTP were significantly decreased in 5-methyl-THF media, possibly reflecting the overall decrease in the precursor UMP, perhaps due to purine-pyrimidine crosstalk.

To evaluate whether these changes were due to aberrant levels of folates, or deficiency of usable 1C units [3], we attempted to rescue these effects through supplementation with the 1C precursor formate. Consistent with this phenotype arising from folate dysregulation, formate did not rescue (Figure 4C-D).

To investigate whether these metabolic changes occur *in vivo*, we examined nucleotide levels from the HCT116 xenografts (Supplementary figure S4A). Elevated levels of GAR (50-fold), FGAR (4-fold), SAICAR (4-fold), and AICAR (7-fold) were observed in the MTR knockouts relative to wild-type controls, mirroring the phenotype observed in cell culture (Figure 4E). In contrast, however, IMP and nucleotides were not consistently depleted in tumors derived from Δ MTR knockouts (Figure 4E, Supplementary figure S4A), suggesting that tumors *in vivo* have other means of maintaining nucleotide homeostasis, perhaps through import of circulating nucleosides. Overall, these results demonstrate that MTR is required for folate species and nucleotide homeostasis under physiological folate conditions.

Discussion

Folate metabolism has long been recognized as a central player in supporting proliferation in tissues and tumors. However, given its complexity, many questions remain pertaining to folate species homeostasis and how dysregulation of folate levels perturbs other areas of cellular metabolism. In this work, we show that despite its name, methionine synthase (MTR) is a minor

immediate source of tissue and tumor methionine, but instead is acutely critical for maintaining folate pools when cells are exposed to physiological folate conditions. Furthermore, we find that MTR loss significantly impairs thymidine and purine biosynthesis, effects not rescued with 1C unit supplementation.

The essentiality of MTR depends on the available extracellular folate species, and its importance is lost when culturing cells using a standard (i.e. folic acid) media preparation. This reflects culture medium typically containing markedly supraphysiological levels of free folate, and lacking physiological levels of 5-methyl-THF. Notably, while there has been recent progress towards more physiological culture medium formulations [41, 42], these continue to employ vitamin levels, including folates, selected for convenience rather than physiological relevance. Future physiological medium should switch to 5-methyl-THF as the primary folate source, and more generally push towards physiological vitamin abundances.

The importance of MTR for growth using 5-methyl-THF as the folate source makes sense based on the pathway architecture. As expected for folate perturbations, intermediates accumulated in both the thymidine and purine pathways. But the ties between the observed changes in folate pools and nucleotide alterations was not obvious. Specifically, purine metabolism was dramatically perturbed by MTR loss, even though its direct folate substrate, 10-formyl-THF, was only modestly affected. Conversely, 5,10-methylene-THF was the most depleted folate species but thymidine levels were maintained. Why the stronger effects on purine metabolism? One possibility is that the structural similarity of different folate cofactors leads to enzyme inhibition by elevated species acting as competitive active site inhibitors. For example, elevated DHF arising from methotrexate treatment is known to inhibit multiple enzymes in folate and purine metabolism [43-45]. Similarly, 5-formyl-THF, and to a lesser extent 5-methyl-THF, have been shown to bind SHMT [46]. In the context of MTR loss, the most likely disrupter of purine synthesis is elevation of 5-methyl-THF. This possibility is supported by the observation that media supplemented with 5-methyl-THF exacerbates purine depletion (Figure 4B, Supplementary figure S4B). Interestingly, recent studies in MTR-null fibroblasts demonstrated buildup of 5-methyl-THF leads to impaired nuclear synthesis of thymidylate, but not purines [34]. However, these cells were cultured in media containing 5-formyl-THF, rather than 5-methyl-THF, bypassing the additional stress imposed by 5-methyl-THF media exposure. Though it remains unproven which enzymatic steps of purine

synthesis are impacted by 5-methyl-THF, the excessive buildup of purine intermediates upstream of AICAR (Figure 4A,C,E) suggests inhibition of AICAR transformylase, the enzyme catalyzing the conversion of AICAR to IMP.

Is there a therapeutic role for MTR inhibitors in the treatment of cancer? Given the substantial success of antifolate treatments in combatting malignancy and MTR's role in maintaining tumor folate pools, targeting MTR, either with a single agent or in combination with other antifolates, merits investigation[47]. Antifolate resistance presents a significant challenge for achieving remission [48, 49], and MTR inhibitors could potentially help in this regard by providing an orthogonal approach to depleting tumor folates and/or by promoting toxic 5-methyl-THF accumulation within tumor cells resistant to other antifolate agents. Side effects could potentially be mitigated by rescue therapy, perhaps with leucovorin, as is common for other anti-folates. To our knowledge, no clinically approved antifolate therapies are known to directly inhibit MTR, though some low potency, folate-like small molecule inhibitors have been reported [50-52]. We look forward to the advancement of such compounds into *in vivo* tools so that the therapeutic potential of MTR inhibition can be more rigorously evaluated.

Materials and Methods

Cell lines, culture conditions and reagents

HCT116, 293T, and HepG2 were obtained from ATCC (Manassas, VA). 8988T cells were obtained from DSMZ (Braunschweig, Germany). Unless otherwise stated, cells were maintained in DMEM (CellGro 10-017, Mediatech) supplemented with 10% fetal bovine serum (FBS, F2442, Sigma-Aldrich). Cell lines were cultured in a 37°C incubator with 5% CO₂ and routinely screened for mycoplasma contamination by PCR. Rowell Park Memorial Institute medium (RPMI, Gibco 11875093; Thermo Fisher) supplemented with 20% FBS (v/v) was used for single-cell plating MTR knockout cells. Folic acid (BP25195) and leucovorin (18-603-788) were obtained from Fisher Scientific; 5-methyl-THF was obtained from Sigma Aldrich (M0132). Isotopic tracers [U-¹³C] methionine (CLM-893-H), [U-¹³C]serine (CLM-1574-H), [3-¹³C] serine (CLM-1572) and [U-²H]betaine (DLM-407-PK) were purchased from Cambridge Isotope Laboratories and stored in stocks of 10 mg/mL at -20°C. All primers were synthesized by IDT

(Coralville, IA). Primers used for sequencing (FWD/REV): MTR-1 = (CCCCAAAGGACACAAGGCTAA/ ACTTGCATTTTCTCCCACCAC); MTR-2 = (AGAAAGCACAGCAGTCCTGAA/ TGGATGTGCCAGCTAGTCAG). Antibodies for Western blotting were used according to their manufacturer's directions. Anti-MTR (25896-1-AP) and Anti-COXIV (11242-1-AP) were obtained from Proteintech. All other standard laboratory chemicals used to make media were obtained from Sigma-Aldrich.

Custom media preparation.

For growth curve experiments, tracer experiments and metabolomics, cells were cultured in DMEM formulated in house from their chemical components. Standard DMEM contains folic acid (4 mg/L). For medias composed of alternative folate species (5-methyl-THF, leucovorin, or both), total folate species concentration was 4 mg/L. In addition, homocysteine (10 mg/mL) and vitamin B₁₂ (1 mg/mL) were added to all custom medias. For tracer media, the amino acid found in standard DMEM was replaced with an equal concentration of tracer amino acid. For formate rescue experiments, sodium formate (141-53-7; Sigma-Aldrich) was added to a final concentration of 1 mM. For tracer, growth and metabolomic experiments, medias were supplemented with 10% (v/v) dialyzed FBS (dFBS, F0392; Sigma-Aldrich). Final media pH was adjusted to ~7.4 prior to sterile filtration using a Stericup Sterile Vacuum filter (SCGPU02RE; MilliporeSigma).

Aqueous metabolite extraction

For aqueous metabolite extraction from cultured cells, cell lines were plated and grown to 80% confluency in 6-well plates in regular DMEM supplemented with 10% FBS or in the described custom folate medias. At start of experiment, cells were washed and media replenished with that indicated (e.g. tracer media, custom folate media, formate media, etc.). After incubation for 4 h under standard conditions, media was rapidly removed by aspiration, cells were washed by PBS 3x, and metabolism was immediately quenched by the addition of 800 μ L of ice cold 40:40:20 acetonitrile:methanol:water (0.5% formic acid). After 1 min of incubation on ice, the extract was neutralized by the addition of NH₄HCO₃ (15% w/v). Samples were incubated at -20°C for ~30 min, then scraped, transferred to Eppendorf tubes, and centrifuged

(15min, 16000 rpm, 4 °C). The resulting supernatant was frozen on dry ice and kept at -80°C until LC-MS analysis.

For extraction of aqueous metabolites from tissues, ~10-mg tissue was disrupted using a Cryomill and lysed in 1 ml ice-cold 40:40:20 acetonitrile:methanol:water (0.5% formic acid) followed by neutralization with 15% w/v ammonium bicarbonate. Solids were precipitated and supernatants were either utilized directly for LC-MS analysis (by HILIC LC-MS) or were dried and resuspended in water (for reverse phase LC-MS).

Folate metabolite extraction.

Folate species were isolated using a previously established protocol [53]. Briefly, cells in culture were seeded at 5×10^6 cells/well in triplicate in 6-well plates maintained for at least 2 doublings in their designated custom folate medias. After aspirating media and washing 3x with PBS, metabolism was quenched with ice-cold extraction buffer (50:50 H₂O:MeOH, 25 mM sodium ascorbate, 25 mM NH₄OAc, pH 7). For xenografts, tumors were weighed and 50 mg of tissue was disrupted via cryomilling. The tissue was then extracted in 1 mL ice-cold buffer (50:50 H₂O:MeOH, 25 mM sodium ascorbate, 25 mM NH₄OAc, pH 7). For both cells and tumors, solids were precipitated by centrifuging at 16000g at 4°C for 10 min. The resulting supernatant was dried under N₂ flow and resuspended in a 50 mM K₃PO₄ solution (30 mM ascorbic acid, 0.5% 2-mercaptoethanol, pH 7). Rat serum (R9759, Sigma-Aldrich) was added and samples incubated at 37°C for 2 hours to cleave polyglutamate tails on folate species. Sample pH was then adjusted to ~4 with formic acid prior to loading on Bond Elut-PH SPE columns (Agilent, 14102005), washing with aqueous buffer (30 mM ascorbic acid, 25 mM NH₄OAc, pH 4.0), and eluting with 50:50 H₂O:MeOH (0.5% 2-mercaptoethanol, 25 mM NH₄OAc, pH 7). Subsequent eluate was dried down under N₂ flow, resuspended in HPLC-grade water, and centrifuged to remove insolubles. The supernatant was then analyzed immediately or stored at -80°C until LC-MS analysis.

Generation of MTR knockout cell lines.

Generation of batch MTR knockout cells in each cell line was achieved using the lentiviral CRISPR–Cas9 vector system LentiCRISPR v2 (Addgene #52961). Briefly, RNA

sequences targeting exon 15 and exon 28 of human *MTR* were designed using the crispr.mit.edu design tool. The guide RNA or scrambled control sequences (Supplementary Table S1) were subcloned into the lentiCRISPR v2 using the BsmBI restriction endonuclease (NEB R0580S). Virus was produced through PEI (MilliporeSigma, 408727) transfection of vectors and lentiviral packaging plasmids psPax2 and VSVG in 293T cells. Medium containing lentivirus was collected after two days and filtered through a PES filter (0.22 μ m, MilliporeSigma). Cells were transfected with virus containing scrambled control or targeting *MTR* and Polybrene (8 μ g/mL, Invitrogen). Cells were split after 48 h into standard RPMI-media (10% FBS) containing puromycin (2 μ g/mL) and cultured for 3 days. The resulting batch knockout cells were suspended in RPMI-media (20% FBS) and plated at a dilution of $\sim$ 1 cell per well in 96-well plates. After 10 days, single colonies were identified and passaged. *MTR* knockout of clonally isolated knockout cells was confirmed by Sanger sequencing and by western blotting.

Cell growth experiments.

Media containing different folate species were formulated in house from their chemical components. Clonally isolated *MTR* knockout cells in the HCT116, 8988T, and HepG2 backgrounds were plated (1 μ L of cells per well) in 6-well plates in the indicated conditions. When approaching confluency (3-5 days depending on cell line), cells were passaged and re-plated at the same dilution (1 μ L of cells per well). Growth was monitored at each point by packed cell volume (PCV). If total well PCV reached 0.5 μ L/mL or lower, the measurements were terminated for that condition.

Subcutaneous xenograft growth studies.

Animal studies were approved and conducted under the supervision of the Princeton University Institutional Animal Care and Use Committee. For tumor growth studies, 7-wk-old female CD1/nude mice were bilaterally injected in the rear flanks with either HCT-116 wild-type, control-1, or Δ MTR-1/2 cells (1×10^6 cells in 100 μ L 1:1 PBS:Matrigel). Tumor growth measurements were taken biweekly using two caliper measurements [volume = $\frac{1}{2}$ (length $\times$ width²)]. Animals were euthanized when tumors reached $\sim$ 1500 mm³ or if they displayed any signs of distress or morbidity. Upon termination of the study, tumors were

isolated, weighed and snap-frozen in liquid nitrogen using a Wollenberger clamp. Tumor tissues were stored at -80°C prior to analysis.

Mouse infusion studies

Animal studies were approved and conducted under the supervision of the Princeton University Institutional Animal Care and Use Committee. PDAC tumor tissues derived from LSL-Kras^{G12D/+}; LSL-Trp53^{R172H/+}; and Pdx-1-Cre (KPC) mice were used to generate a syngeneic xenograft model, as previously described [38]. Briefly, tumor tissues were minced, mixed with Matrigel (Corning Cat #354234 in 1:1 ratio (v/v)) and injected (200 µL) into the subcutaneous left flank of C57BL/6J mice (Charles River). Tumors were allowed to grow until palpable, at which point jugular vein catheter placement surgery was performed. Mice were single-housed and allowed to recover for 7 days following surgery. On day of infusion, food was removed ~6 h prior to start. Isotope tracers in saline ([U-¹³C]methionine, 40 mM, 0.1 µl/g/min; [U-¹³C]serine, 50 mM, 0.1 µl/g/min) were infused via the catheter. After 2.5 h, serum was collected via the tail vein. Mice were euthanized via cervical dislocation and tissues (including tumor) were isolated immediately and snap-frozen in liquid nitrogen using a Wollenberger clamp to preserve metabolite levels. For betaine infusions [U-²H]betaine (50 mM, 0.1 µl/g/min), pre-catheterized, non-tumor bearing C57BL/6J mice from Charles River were utilized and infused for 4 h. All tissues were snap frozen using a Wollenberger clamp and stored at -80°C prior to analysis.

LC-MS Analysis

Aqueous metabolites were analyzed using a quadrupole-orbitrap mass spectrometer (Q Exactive Plus, Thermo Fisher Scientific, Waltham, MA), coupled to hydrophilic interaction chromatography (HILIC) with LC separation on a XBridge BEH Amide column (Waters), and a stand-alone orbitrap (Thermo-Fisher Exactive) coupled to reversed-phase ion-pairing chromatography with LC separation on a HSS-T3 column (Waters). Both mass spectrometers were coupled to their respective liquid chromatography methods via electrospray-ionization and were operating in negative ion mode with a scan range m/z 75-1000. Detailed analytical conditions have been previously described [54, 55]. Betaine measurements were made using a Q Exactive Plus operating in positive ion mode with a scan range m/z 75-1000 coupled via

electrospray-ionization to reverse-phase chromatography with LC separation on an Agilent Poroshell 120 Bonus-RP column [56]. Folate extracts were analyzed by Q Exactive Plus operating in negative ion mode with a scan range m/z 350-1000, coupled via electrospray-ionization to reverse-phase chromatography with LC separation on an Agilent Poroshell 120 Bonus-RP column. Cell culture metabolite abundances were normalized by packed cell volume; tissues and tumor metabolite abundances were normalized by mass. Isotopic labeling of metabolites arising from ^{13}C -labeled nutrients were corrected for natural abundance [57]. All LC-MS data was analyzed using the EIMaven software (v 0.2.4, Elucidata), with compounds identified based on exact mass and retention time matched to commercial standards.

Statistics

Samples sizes are defined in each figure legend. Results for biological replicates are presented as mean $\pm$ SD or mean $\pm$ SEM, as noted in figure legends. Statistical significance was calculated using unpaired Student's t-test when comparing two groups, and one-way ANOVA followed by Dunnett's post hoc analysis when comparing three or more. All statistical calculations were performed using the software package GraphPad Prism 7.03.

Acknowledgments

We thank Wenyun Lu and other members of the Rabinowitz laboratory for helpful comments and suggestions. LentiCRISPR v2 was a gift from Feng Zhang (Addgene plasmid # 52961). This work was supported by NIH grants 1DP1DK113643 and R01 CA163591 to J.D.R.

Author contributions

J.M.G. conceived the study. J.M.G., J.Z.W., and J.D.R. designed the experiments. J.Z.W., J.M.G., and L.Y. conducted the experiments. J.Z.W., J.M.G., and J.D.R. wrote the paper with input from L.Y.

References

1. Voet, D., J.G. Voet, and C.W. Pratt, Fundamentals of biochemistry: life at the molecular level. **2016**.
2. Tibbetts, A.S. and D.R. Appling, Compartmentalization of Mammalian folate-mediated one-carbon metabolism. *Annu Rev Nutr*, **2010**. 30: p. 57-81.
3. Ducker, G.S., L. Chen, R.J. Morscher, J.M. Ghergurovich, M. Esposito, X. Teng, *et al.*, Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway. *Cell Metab*, **2016**. 23(6): p. 1140-53.
4. Fox, J.T. and P.J. Stover, *Chapter 1 Folate-Mediated One-Carbon Metabolism*, in *Vitamins & Hormones*. 2008, Academic Press. p. 1-44.
5. Dudman, N.P., P. Slowiaczek, and M.H. Tattersall, Methotrexate rescue by 5-methyltetrahydrofolate or 5-formyltetrahydrofolate in lymphoblast cell lines. *Cancer Res*, **1982**. 42(2): p. 502-7.
6. Ducker, G.S. and J.D. Rabinowitz, One-Carbon Metabolism in Health and Disease. *Cell Metab*, **2017**. 25(1): p. 27-42.
7. Labuschagne, C.F., N.J. van den Broek, G.M. Mackay, K.H. Vousden, and O.D. Maddocks, Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. *Cell Rep*, **2014**. 7(4): p. 1248-58.
8. Wright, A.J., P.M. Finglas, J.R. Dainty, C.A. Wolfe, D.J. Hart, D.M. Wright, *et al.*, Differential kinetic behavior and distribution for pteroylglutamic acid and reduced folates: a revised hypothesis of the primary site of PteGlu metabolism in humans. *J Nutr*, **2005**. 135(3): p. 619-23.
9. Patanwala, I., M.J. King, D.A. Barrett, J. Rose, R. Jackson, M. Hudson, *et al.*, Folic acid handling by the human gut: implications for food fortification and supplementation. *Am J Clin Nutr*, **2014**. 100(2): p. 593-9.
10. Običan, S.G., R.H. Finnell, J.L. Mills, G.M. Shaw, and A.R. Scialli, Folic acid in early pregnancy: a public health success story. *The FASEB Journal*, **2010**. 24(11): p. 4167-74.
11. Finkelstein, J.D., Methionine metabolism in mammals. *J Nutr Biochem*, **1990**. 1(5): p. 228-37.
12. Rose, W.C., J.E. Johnson, and W.J. Haines, The amino acid requirements of man. 1. The role of valine and methionine. *Journal of Biological Chemistry*, **1950**. 182: p. 541-56.
13. Sowers, J.E., W.L. Stockland, and R.J. Meade, L-Methionine and L-Cystine Requirements of the Growing Rat. *Journal of Animal Science*, **1972**. 35(4): p. 782-88.
14. Lu, S.C., S-adenosylmethionine. *The international journal of biochemistry & cell biology*, **2000**. 32(4): p. 391-95.
15. Finkelstein, J.D., Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. *Clin Chem Lab Med*, **2007**. 45(12): p. 1694-9.
16. Zheng, Y., S. Ramsamooj, Q. Li, J.L. Johnson, T.M. Yaron, K. Sharra, *et al.*, Regulation of folate and methionine metabolism by multisite phosphorylation of human methylenetetrahydrofolate reductase. *Scientific Reports*, **2019**. 9(1): p. 4190.
17. Baker, D.H. and G.L. Czarnecki, Transmethylation of Homocysteine to Methionine: Efficiency in the Rat and Chick. *The Journal of Nutrition*, **1985**. 115(10): p. 1291-99.
18. Bennett, M.A., UTILIZATION OF HOMOCYSTINE FOR GROWTH IN PRESENCE OF VITAMIN B12 AND FOLIC ACID. *Journal of Biological Chemistry*, **1950**. 187(2): p. 751-56.

19. du Vigneaud, V., C. Ressler, and J.R. Rachele, The Biological Synthesis of "Labile Methyl Groups". *Science*, **1950**. 112(2906): p. 267-71.
20. Banerjee, R.V. and R.G. Matthews, Cobalamin-dependent methionine synthase. *The FASEB Journal*, **1990**. 4(5): p. 1450-59.
21. Watkins, D. and D.S. Rosenblatt, Inborn errors of cobalamin absorption and metabolism. *American Journal of Medical Genetics Part C: Seminars in Medical Genetics*, **2011**. 157(1): p. 33-44.
22. Watkins, D., M. Ru, H.-Y. Hwang, C.D. Kim, A. Murray, N.S. Philip, *et al.*, Hyperhomocysteinemia due to methionine synthase deficiency, cblG: structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173L. *American journal of human genetics*, **2002**. 71(1): p. 143-53.
23. Swanson, D.A., M.L. Liu, P.J. Baker, L. Garrett, M. Stitzel, J. Wu, *et al.*, Targeted disruption of the methionine synthase gene in mice. *Mol Cell Biol*, **2001**. 21(4): p. 1058-65.
24. Geiger, T., A. Velic, B. Macek, E. Lundberg, C. Kampf, N. Nagaraj, *et al.*, Initial Quantitative Proteomic Map of 28 Mouse Tissues Using the SILAC Mouse. *Molecular & Cellular Proteomics*, **2013**. 12(6): p. 1709-22.
25. Uhlen, M., L. Fagerberg, B.M. Hallstrom, C. Lindskog, P. Oksvold, A. Mardinoglu, *et al.*, Proteomics. Tissue-based map of the human proteome. *Science*, **2015**. 347(6220): p. 1260419.
26. Pajares, M.A. and D. Pérez-Sala, Betaine homocysteine S-methyltransferase: just a regulator of homocysteine metabolism? *Cellular and Molecular Life Sciences CMLS*, **2006**. 63(23): p. 2792-803.
27. Zhang, W., A. Braun, Z. Bauman, H. Olteanu, P. Madzalan, and R. Banerjee, Expression profiling of homocysteine junction enzymes in the NCI60 panel of human cancer cell lines. *Cancer Res*, **2005**. 65(4): p. 1554-60.
28. Uhlen, M., C. Zhang, S. Lee, E. Sjostedt, L. Fagerberg, G. Bidkhori, *et al.*, A pathology atlas of the human cancer transcriptome. *Science*, **2017**. 357(6352).
29. Hoffbrand, A.V. and A.H. Waters, Observations on the Biochemical Basis of Megaloblastic Anaemia. *British Journal of Haematology*, **1972**. 23(s1): p. 109-18.
30. Shane, B. and E.R. Stokstad, Vitamin B12-folate interrelationships. *Annual review of nutrition*, **1985**. 5(1): p. 115-41.
31. Kondo, H., M.L. Osborne, J.F. Kolhouse, M.J. Binder, E.R. Podell, C.S. Utley, *et al.*, Nitrous oxide has multiple deleterious effects on cobalamin metabolism and causes decreases in activities of both mammalian cobalamin-dependent enzymes in rats. *The Journal of clinical investigation*, **1981**. 67(5): p. 1270-83.
32. Horne, D.W. and W.T. Briggs, Effect of Dietary and Nitrous Oxide-Induced Vitamin B-12 Deficiency on Uptake of 5-Methyltetrahydrofolate by Isolated Rat Hepatocytes. *The Journal of Nutrition*, **1980**. 110(2): p. 223-30.
33. Matthews, R.G. and J.T. Drummond, Providing one-carbon units for biological methylations: mechanistic studies on serine hydroxymethyltransferase, methylenetetrahydrofolate reductase, and methyltetrahydrofolate-homocysteine methyltransferase. *Chemical Reviews*, **1990**. 90(7): p. 1275-90.
34. Palmer, A.M., E. Kamynina, M.S. Field, and P.J. Stover, Folate rescues vitamin B₁₂ depletion-induced inhibition of nuclear thymidylate biosynthesis and genome instability. *Proceedings of the National Academy of Sciences*, **2017**. 114(20): p. E4095-E102.

35. Herbert, V. and R. Zalusky, INTERRELATIONS OF VITAMIN B12 AND FOLIC ACID METABOLISM: FOLIC ACID CLEARANCE STUDIES. *The Journal of Clinical Investigation*, **1962**. 41(6): p. 1263-76.
36. Noronha, J. *On folic acid, vitamin B12, methionine and formiminoglutamic acid metabolism*. in *Second European Symposium on Vitamin B12 and Intrinsic Factor, 1962*. 1962.
37. Maddocks, O.D., C.F. Labuschagne, P.D. Adams, and K.H. Vousden, Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP Synthesis in Cancer Cells. *Mol Cell*, **2016**. 61(2): p. 210-21.
38. Yang, L., J.C. Garcia Canaveras, Z. Chen, L. Wang, L. Liang, C. Jang, *et al.*, Serine Catabolism Feeds NADH when Respiration Is Impaired. *Cell Metab*, **2020**. 31(4): p. 809-21 e6.
39. Sunden, S.L., M.S. Renduchintala, E.I. Park, S.D. Miklasz, and T.A. Garrow, Betaine-homocysteine methyltransferase expression in porcine and human tissues and chromosomal localization of the human gene. *Arch Biochem Biophys*, **1997**. 345(1): p. 171-4.
40. Fazili, Z., C.M. Pfeiffer, and M. Zhang, Comparison of serum folate species analyzed by LC-MS/MS with total folate measured by microbiologic assay and Bio-Rad radioassay. *Clin Chem*, **2007**. 53(4): p. 781-4.
41. Cantor, J.R., M. Abu-Remaileh, N. Kanarek, E. Freinkman, X. Gao, A. Louissaint, *et al.*, Physiologic Medium Rewires Cellular Metabolism and Reveals Uric Acid as an Endogenous Inhibitor of UMP Synthase. *Cell*, **2017**. 169(2): p. 258-72.e17.
42. Vande Voorde, J., T. Ackermann, N. Pfetzer, D. Sumpton, G. Mackay, G. Kalna, *et al.*, Improving the metabolic fidelity of cancer models with a physiological cell culture medium. *Science Advances*, **2019**. 5(1): p. eaau7314.
43. Kwon, Y.K., W. Lu, E. Melamud, N. Khanam, A. Bogner, and J.D. Rabinowitz, A domino effect in antifolate drug action in Escherichia coli. *Nat Chem Biol*, **2008**. 4(10): p. 602-8.
44. Allegra, C.J., J.C. Drake, J. Jolivet, and B.A. Chabner, Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. *Proceedings of the National Academy of Sciences of the United States of America*, **1985**. 82(15): p. 4881-85.
45. Allegra, C.J., K. Hoang, G.C. Yeh, J.C. Drake, and J. Baram, Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. *J Biol Chem*, **1987**. 262(28): p. 13520-6.
46. Stover, P. and V. Schirch, 5-Formyltetrahydrofolate polyglutamates are slow tight binding inhibitors of serine hydroxymethyltransferase. *Journal of Biological Chemistry*, **1991**. 266(3): p. 1543-50.
47. Matthews, R.G., J.T. Drummond, and H.K. Webb, Cobalamin-dependent methionine synthase and serine hydroxymethyltransferase: targets for chemotherapeutic intervention? *Advances in enzyme regulation*, **1998**. 38: p. 377-92.
48. Walling, J., From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. *Investigational New Drugs*, **2006**. 24(1): p. 37-77.
49. Gonen, N. and Y.G. Assaraf, Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance. *Drug Resistance Updates*, **2012**. 15(4): p. 183-210.

50. Zhang, Z., C. Tian, S. Zhou, W. Wang, Y. Guo, J. Xia, *et al.*, Mechanism-based design, synthesis and biological studies of N⁵-substituted tetrahydrofolate analogs as inhibitors of cobalamin-dependent methionine synthase and potential anticancer agents. *Eur J Med Chem*, **2012**. 58: p. 228-36.
51. Tang, C., Z. Zhang, B. Xu, M. Li, J. Liu, and J. Cui, Two newly synthesized 5-methyltetrahydrofolate-like compounds inhibit methionine synthase activity accompanied by cell cycle arrest in G1/S phase and apoptosis in vitro. *Anticancer Drugs*, **2008**. 19(7): p. 697-704.
52. Banks, E.C., S.W. Doughty, S.M. Toms, R.T. Wheelhouse, and A. Nicolaou, Inhibition of cobalamin-dependent methionine synthase by substituted benzo-fused heterocycles. *Febs j*, **2007**. 274(1): p. 287-99.
53. Chen, L., G.S. Ducker, W. Lu, X. Teng, and J.D. Rabinowitz, An LC-MS chemical derivatization method for the measurement of five different one-carbon states of cellular tetrahydrofolate. *Anal Bioanal Chem*, **2017**. 409(25): p. 5955-64.
54. Lu, W., M.F. Clasquin, E. Melamud, D. Amador-Noguez, A.A. Caudy, and J.D. Rabinowitz, Metabolomic analysis via reversed-phase ion-pairing liquid chromatography coupled to a stand alone orbitrap mass spectrometer. *Anal Chem*, **2010**. 82(8): p. 3212-21.
55. Wang, L., X. Xing, L. Chen, L. Yang, X. Su, H. Rabitz, *et al.*, Peak Annotation and Verification Engine for Untargeted LC-MS Metabolomics. *Analytical Chemistry*, **2019**. 91(3): p. 1838-46.
56. Poillet-Perez, L., X. Xie, L. Zhan, Y. Yang, D.W. Sharp, Z.S. Hu, *et al.*, Autophagy maintains tumour growth through circulating arginine. *Nature*, **2018**. 563(7732): p. 569-73.
57. Su, X., W. Lu, and J.D. Rabinowitz, Metabolite Spectral Accuracy on Orbitraps. *Anal Chem*, **2017**. 89(11): p. 5940-48.
58. Ghandi, M., F.W. Huang, J. Jané-Valbuena, G.V. Kryukov, C.C. Lo, E.R. McDonald, *et al.*, Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature*, **2019**. 569(7757): p. 503-08.

Figure Legends

Figure 1. MTR is a minor source of methionine in cell lines, tissues and tumors

(A) Schematic showing the activity of MTR at the intersection of the folate and methionine cycles. MTR = methionine synthase, MTHFR = methylenetetrahydrofolate reductase, BHMT = betaine-homocysteine S-methyltransferase, SHMT = serine hydroxymethyltransferase. (B) Relative protein levels of MTR and BHMT in mice from [24]. (C) Methionine labeling in cell lines after culturing for 4 h in media containing [U-¹³C]methionine (mean ± SD, n = 2 for HCT116 cells, 3 for 293T and HepG2). (D) Methionine labeling of serum, PDAC tumors, and normal tissues in C57BL/6J mice after [U-¹³C]methionine infusion for 2.5 h (mean ± SD, n=3 mice; two technical replicates were included for each tumor). (E) Methionine labeling in normal tissues in C57BL/6J mice after [U-²H]betaine infusion for 4 h (mean ± SD, n=1 infusion; two technical replicates for each tissue).

Figure 2. MTR is essential for cell and tumor growth under physiological conditions.

(A) Western blot analysis of MTR in HCT116, 8988T and HepG2 clonally isolated lines after treatment with lentiviral CRISPR-Cas9 targeting scrambled control (control-1) or *MTR* (Δ MTR-1 and Δ MTR-2). (B) Cell growth curves in the media containing indicated folate sources (mean ± SD, n=2). 5-meTHF = 5-methyl-tetrahydrofolate. (C) Growth of subcutaneous HCT116 xenografts (mean ± SEM, n=10 mice, Student's t-test). ** = p < 0.01, *** = p < 0.001 for comparison to respective controls. WT = wild-type.

Figure 3. Loss of MTR results in the elevation of 5-methyl-THF and depletion of other folate species

(A) Relative abundance of folate species in HCT116 control and MTR knockout cells in culture across media with indicated folate sources. Intensities are normalized to the average of control-1 cells in folic acid (mean ± SD, n=2, one-way ANOVA, p-values compare control to MTR knockout in the same medium). (B) Relative abundance of folate species in HCT116 control and MTR knockout subcutaneous tumors. For each condition, individual biological replicates are

shown, normalized to control tumors and analyzed in parallel by LC-MS. DHF = dihydrofolate, THF = tetrahydrofolate. TIC = total ion count, * = $p < 0.05$, n.s. = not significant.

Figure 4. MTR supports purine biosynthesis by promoting folate availability

Relative abundance of (A) purine biosynthetic intermediates and (B) nucleotides in HCT116 control and MTR knockout cells in culture with indicated folate sources. Intensities are normalized to the average of control-1 cells in folic acid (mean $\pm$ SD, n=3). Relative abundance of (C) purine biosynthetic intermediate and (D) nucleotides in control and MTR knockout cells grown in media with 5-methyl-THF, with and without the addition of 1 mM formate (mean $\pm$ SD, n=3). (E) Relative abundance of purine biosynthetic intermediate and nucleotide triphosphates in HCT116 control and MTR knockout subcutaneous tumors. For each condition, individual biological replicates are shown, normalized to wild-type tumors and analyzed in parallel by LC-MS. TIC = total ion count, * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, n.s. = not significant. WT = wild-type.

Figure 1. MTR is a minor source of methionine in cell lines, tissues and tumors

Figure 2. MTR is essential for cell and tumor growth under physiological conditions.

Figure 3. Loss of MTR results in the elevation of 5-methyl-THF and depletion of other folate species.

Figure 4. MTR supports purine biosynthesis by promoting folate availability.